TrialCardiovascular diabetology2017

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.

Toshiyuki Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.